Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Barasertib |
Synonyms | |
Therapy Description |
Barasertib (AZD1152) is a selective Aurora B kinase inhibitor, which induces cell cycle arrest (PMID: 17495131, PMID: 30540594). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Barasertib | AZD1152|AZD-1152 | Aurkb Inhibitors 21 | Barasertib (AZD1152) is a selective Aurora B kinase inhibitor, which induces cell cycle arrest (PMID: 17495131, PMID: 30540594). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
SMARCB1 loss | epithelioid sarcoma | sensitive | Barasertib | Preclinical - Cell culture | Actionable | In a preclinical study, Barasertib (AZD1152) inhibited viability of SMARCB1-deficient epithelioid sarcoma cell lines in culture (PMID: 38315003). | 38315003 |
RB1 del SMARCB1 loss | rhabdoid cancer | sensitive | Barasertib | Preclinical - Cell culture | Actionable | In a preclinical study, Barasertib (AZD1152) inhibited viability of a SMARCB1-deficient rhabdoid cancer cell line with a deletion of RB1 in culture (PMID: 38315003). | 38315003 |
SMARCB1 loss | rhabdoid cancer | sensitive | Barasertib | Preclinical - Cell culture | Actionable | In a preclinical study, Barasertib (AZD1152) inhibited viability of SMARCB1-deficient rhabdoid cancer cell lines in culture (PMID: 38315003). | 38315003 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|